Case 3: Faricimab in a neovascular nAMD patient with persistent fluid

Video

Dr. Khanani discusses how switching to faricimab helped resolve persistent intraretinal and subretinal fluid in a patient and extended treatment intervals leading to decreased patient burden.

Sponsored by Roche

© 2024 MJH Life Sciences

All rights reserved.